ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 2536 • ACR Convergence 2024

    Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium

    Kevin Bu1, Rebecca Blank2, Adam Cantor1, Alba Boix-Amoros3, Jose Scher4 and Jose Clemente1, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), 1Icahn School of Medicine at Mount Sinai, New York, NY, 2NYU, New York, NY, 3Icahn School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY

    Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
  • Abstract Number: 0147 • ACR Convergence 2024

    Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis

    Ilana Usiskin1, Mary Jeffway1, Feng Liu1, Nancy Shadick1, Michael Weinblatt2, Brittany Weber3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 3Brigham and Women's Hospital, DEDHAM, MA

    Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
  • Abstract Number: 0515 • ACR Convergence 2024

    Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis

    Olivia Posey, Anastasiia Phothisane, Phicharmon Kulapatana and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Neutrophils contribute to the innate immune response of killing pathogens through the formation of neutrophil extracellular traps (NETs), which is also called NETosis. NETosis…
  • Abstract Number: 0834 • ACR Convergence 2024

    Evolution of Lung Inflammation in a Mouse Model of Chronic/Recurrent Macrophage Activation Syndrome

    Richard Chhaing, Natsumi Inoue, Jana Latayan and grant schulert, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD) is a life-threatening complication and associated in >80% of cases with macrophage activation syndrome (MAS); however, the…
  • Abstract Number: 0951 • ACR Convergence 2024

    A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis

    Stavros Giaglis1, Diego Kyburz2 and Ulrich Walker3, 1Experimental Rheumatology Laboratory, University of Basel, Basel, Switzerland, 2University Hospital Basel, Basel, Switzerland, 3Basel University Hospital, Basel, Switzerland

    Background/Purpose: Mitochondria are essential eucaryotic cell organelles with several bacterial features, such as a double-stranded circular genome with hypomethylated CpG areas (1). A fundamental role of…
  • Abstract Number: 1567 • ACR Convergence 2024

    Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis

    Chin Yit Soo1, Nicholas Jex2, Stefano Di Donato3, Lucy Elizabeth Thornton4, Vishal Kakkar5, Riccardo Bixio6, Raluca Tomoaia1, Thomas Anderton2, May Lwin2, Christel Kamani2, Amrit Chowdhary2, Henry Procter1, Sharmaine Thirunavukarasu1, Sindhoora Kotha2, Marilena Giannoudi2, Eylem Levelt2, Sven Plein1, Francesco Delgado6 and Lesley-Anne Bissell7, 1Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, England, United Kingdom, 2Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, 31. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 41. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, 5University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, 7Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Primary cardiac involvement in systemic sclerosis (SSc) is heterogenous, poorly defined and associated with significant cardiac morbidity and mortality. The underlying mechanism is not…
  • Abstract Number: 1810 • ACR Convergence 2024

    Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus

    Ksenia Anufrieva1, Rochelle Castillo2, Ce Gao2, Jessica Liu2, Neda Shahriari2, Kimberly Hashemi2, Dustin Taylor3, Rachael Rowley2, Elizabeth Rainone2, Avery LaChance2, Rachel Gate4, ilya Korsunsky2, Ruth Ann Vleugels5 and Kevin Wei6, 1BWH, Cambridge, MA, 2Brigham and Women's Hospital, Boston, MA, 3Vanderbilt University Medical Center, Nashville, TN, 410x Genomics, Pleasanton, CA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA

    Background/Purpose: Reliable and effective treatments for refractory cutaneous lupus erythematosus (CLE) remained elusive until the arrival of anifrolumab, a monoclonal antibody targeting the type I…
  • Abstract Number: 2032 • ACR Convergence 2024

    A Systematic Review of Treatment Strategies in VEXAS Syndrome

    Aviraag Vijaya Prakash1, Jose Garcia2, Anurag Goel3, Vinit Gilvaz4 and Raveena Midha5, 1Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, 2Brown University, East Greenwich, RI, 3The Warren Alpert Medical School of Brown University, Providence, RI, 4The Warren Alpert Medical School of Brown University, East Providence, RI, 5Kent Hospital/Brown University, Warwick, RI

    Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…
  • Abstract Number: 2557 • ACR Convergence 2024

    The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study

    Zhiqiang Wang1, Sarah Tilley2, Christine Peloquin2, Eva Petrow3, Margaret Clancy2 and Tuhina Neogi2, 1Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3Boston Medical Center, Boston, MA

    Background/Purpose: Colchicine, an anti-inflammatory drug commonly used in gout, has been associated with a lower incidence of total knee/hip replacement compared to placebo among participants…
  • Abstract Number: 0023 • ACR Convergence 2024

    Adenosine and Guanosine-based Oligonucleotide Attenuates Catabolic Phenotypes in Chondrocytes and Slows Progression of Surgically Induced Osteoarthritis

    Yoonhee Kim1, Jin Han2 and Seungwoo Han3, 1Kyungpook National University School of Medicine, Buk-gu, Daegu, Republic of Korea, 2Kyungpook National University, Buk-gu, Daegu, Republic of Korea, 3Kyungpook national university hospital, Daegu, South Korea

    Background/Purpose: Adenosine is a potent endogenous modulator of inflammation; however, its clinical application is limited due to its extremely short half-life in blood. In this…
  • Abstract Number: 0230 • ACR Convergence 2024

    Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients with Inflammatory Bowel Disease – Clinical and MRI Findings from a Population-Based Cohort Study

    Nora Vladimirova1, Jakob Møller2, Mohamed Attauabi2, Gorm Madsen3, Lene Terslev4, Charlotte Wiell5, Viktoria Fana6, Sanja Bay Hansen3, Hartwig Siebner3, Jakob Seidelin2, Flemming Bentsen3, Kasper Gosvig7, Johan Burisch3 and Mikkel Ostergaard8, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, 2Herlev and Gentofte Hospital, copenhagen, Denmark, 3Hvidovre Hospital, copenhagen, Denmark, 4Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, 5Rigshospitalet-Glostrup, Copenhagen, Denmark, 6Rigshospitalet-Glostrup, Glostrup, Denmark, 7Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, 8Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark

    Background/Purpose: In patients with inflammatory bowel disease (IBD), coexistence of spondyloarthritis (SpA), the most common extraintestinal manifestation, is associated with poor outcomes and impaired quality…
  • Abstract Number: 0562 • ACR Convergence 2024

    Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study

    Lucia Ondrejčáková1, Adéla Navrátilová2, Monika Gregová3, Kristýna Bubová4, Tomáš Grega5, Ladislav Šenolt6, Karel Pavelka7 and Lucie Andrés Cerezo8, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, 21st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, 4Institute of Rheumatology and Charles University, Prague, Czech Republic, 53Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 7Institute of Rheumatology and Charles University, Praha, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
  • Abstract Number: 0846 • ACR Convergence 2024

    Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years

    Sharan Rai1, Hyon K. Choi2, Chio Yokose1 and Natalie McCormick1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Only 20% of those with hyperuricemia develop clinically evident gout, suggesting that other, likely inflammatory, factors influence NLRP3 inflammasome activation and progression to gout.…
  • Abstract Number: 0957 • ACR Convergence 2024

    Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement

    Laura Much1, Elena Pachera2, Andrea Laimbacher1, Henriette Didriksen3, Lars Aabakken4, Knut Ea Lundin4, Lumeng Li1, Astrid Hofman1, Pietro Bearzi5, Sophie Wagner6, Michael Scharl7, Øyvind Molberg8, Håvard Fretheim9, Oliver Distler10 and Anna-Maria Hoffmann-Vold9, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3Oslo University Hospital, Moss, Norway, 4Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 6University of Zurich, Schlieren, Switzerland, 7Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 9Oslo University Hospital, Oslo, Norway, 10Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…
  • Abstract Number: 1577 • ACR Convergence 2024

    Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog

    Neda Kortam1, Wenying Liang1, Claire Shiple1, Suiyuan Huang1, Rosemary Gedert1, James St. Clair1, Cyrus Sarosh2, Caroline Foster1, Eliza Pei-Suen Tsou1, John Varga1, Jason Knight1, Dinesh Khanna1 and Ramadan Ali1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Temperance, MI

    Background/Purpose: Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology